PT4003988T - Derivados de 3,6-diamino-piridazin-3-ilo, composies farmacuticas contendo os mesmos e as suas utilizaes como agentes pr-apoptticos - Google Patents

Derivados de 3,6-diamino-piridazin-3-ilo, composies farmacuticas contendo os mesmos e as suas utilizaes como agentes pr-apoptticos

Info

Publication number
PT4003988T
PT4003988T PT207498338T PT20749833T PT4003988T PT 4003988 T PT4003988 T PT 4003988T PT 207498338 T PT207498338 T PT 207498338T PT 20749833 T PT20749833 T PT 20749833T PT 4003988 T PT4003988 T PT 4003988T
Authority
PT
Portugal
Prior art keywords
pyridazin
diamino
pro
derivatives
pharmaceutical compositions
Prior art date
Application number
PT207498338T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of PT4003988T publication Critical patent/PT4003988T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
PT207498338T 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composies farmacuticas contendo os mesmos e as suas utilizaes como agentes pr-apoptticos PT4003988T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29

Publications (1)

Publication Number Publication Date
PT4003988T true PT4003988T (pt) 2026-07-20

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207498338T PT4003988T (pt) 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composies farmacuticas contendo os mesmos e as suas utilizaes como agentes pr-apoptticos

Country Status (30)

Country Link
US (1) US12649733B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003988B1 (cg-RX-API-DMAC7.html)
JP (1) JP7646626B2 (cg-RX-API-DMAC7.html)
KR (1) KR102987770B1 (cg-RX-API-DMAC7.html)
CN (1) CN114450283B (cg-RX-API-DMAC7.html)
AR (1) AR119493A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020322072B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001330A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021003594A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000700A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220014A (cg-RX-API-DMAC7.html)
DK (1) DK4003988T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000015A (cg-RX-API-DMAC7.html)
ES (1) ES3074241T3 (cg-RX-API-DMAC7.html)
FI (1) FI4003988T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247670B (cg-RX-API-DMAC7.html)
IL (1) IL289932B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20220006A1 (cg-RX-API-DMAC7.html)
LT (1) LT4003988T (cg-RX-API-DMAC7.html)
MA (1) MA56644B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001161A (cg-RX-API-DMAC7.html)
PE (1) PE20220704A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550018A1 (cg-RX-API-DMAC7.html)
PT (1) PT4003988T (cg-RX-API-DMAC7.html)
PY (1) PY2039849A (cg-RX-API-DMAC7.html)
SA (1) SA522431498B1 (cg-RX-API-DMAC7.html)
TW (1) TWI900486B (cg-RX-API-DMAC7.html)
UA (1) UA130870C2 (cg-RX-API-DMAC7.html)
UY (1) UY38809A (cg-RX-API-DMAC7.html)
WO (1) WO2021018857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116761635A (zh) * 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3229844B1 (en) 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
JP2018502839A (ja) 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
US10124004B2 (en) * 2015-05-29 2018-11-13 Teijin Pharma Limited Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
MX2018015284A (es) 2016-06-08 2019-09-18 Abbvie Inc Conjugados de anticuerpo anti-egfr y fármaco.

Also Published As

Publication number Publication date
IL289932B1 (en) 2025-10-01
KR102987770B1 (ko) 2026-07-07
ES3074241T3 (en) 2026-07-20
WO2021018857A1 (en) 2021-02-04
PE20220704A1 (es) 2022-05-04
SA522431498B1 (ar) 2025-04-13
MA56644B1 (fr) 2026-06-30
EP4003988A1 (en) 2022-06-01
PY2039849A (es) 2021-05-06
FI4003988T3 (fi) 2026-07-10
JOP20220006A1 (ar) 2023-01-30
NZ784583A (en) 2025-02-28
PH12022550018A1 (en) 2022-10-17
GEAP202415866A (en) 2024-06-10
CO2022000700A2 (es) 2022-02-07
UA130870C2 (uk) 2026-06-03
KR20220042182A (ko) 2022-04-04
DOP2022000015A (es) 2022-05-15
IL289932A (en) 2022-03-01
CA3148502A1 (en) 2021-02-04
CN114450283B (zh) 2024-05-07
CR20220014A (es) 2022-03-02
AR119493A1 (es) 2021-12-22
JP2022542937A (ja) 2022-10-07
US20220289734A1 (en) 2022-09-15
UY38809A (es) 2021-02-26
MX2022001161A (es) 2022-02-22
LT4003988T (lt) 2026-07-10
CN114450283A (zh) 2022-05-06
AU2020322072A1 (en) 2022-02-10
AU2020322072B2 (en) 2026-06-25
GEP20247670B (en) 2024-09-25
US12649733B2 (en) 2026-06-09
IL289932B2 (en) 2026-02-01
TWI900486B (zh) 2025-10-11
CL2021003594A1 (es) 2022-11-18
DK4003988T3 (da) 2026-06-15
TW202118761A (zh) 2021-05-16
JP7646626B2 (ja) 2025-03-17
EP4003988B1 (en) 2026-05-20
BR112022001330A2 (pt) 2022-05-17